Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Non-Current Deferred Tax Liability: 2023-2024

Historic Non-Current Deferred Tax Liability for Iovance Biotherapeutics (IOVA) over the last 2 years, with Dec 2024 value amounting to $32.3 million.

  • Iovance Biotherapeutics' Non-Current Deferred Tax Liability was N/A to $31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.7 million, marking a year-over-year change of. This contributed to the annual value of $32.3 million for FY2024, which is 86.29% up from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Non-Current Deferred Tax Liability of $32.3 million as of FY2024, which was up 86.29% from $17.3 million recorded in FY2023.
  • In the past 5 years, Iovance Biotherapeutics' Non-Current Deferred Tax Liability ranged from a high of $32.3 million in FY2024 and a low of $17.3 million during FY2023.
  • In the last 2 years, Iovance Biotherapeutics' Non-Current Deferred Tax Liability had a median value of $24.8 million in 2023 and averaged $24.8 million.
  • Data for Iovance Biotherapeutics' Non-Current Deferred Tax Liability shows a peak YoY soared of 86.29% (in 2024) over the last 5 years.
  • Iovance Biotherapeutics' Non-Current Deferred Tax Liability (Yearly) stood at $17.3 million in 2023, then soared by 86.29% to $32.3 million in 2024.